Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Should Use “Bully Pulpit” To Lower MRI Accident Rate, Workshop Goers Say

This article was originally published in The Gray Sheet

Executive Summary

While overseeing MRI operators is outside FDA's purview, participants at an FDA workshop agreed that the agency should use its “bully pulpit” to at least encourage safer use of magnetic resonance imaging equipment.

You may also be interested in...



Tragic MRI Accident In Mumbai Emphasizes Needs For Training And Tech

An incident involving the death of a Mumbai, India man who brought a metal liquid oxygen cylinder into an MRI suite and died from inhaling oxygen after being sucked into the machine with the container – which was damaged and started leaking oxygen – was preventable, investigators are saying. The incident also serves as a teachable moment on the need to prevent entries into MRI suites of people carrying ferrous objects, say experts familiar with MRI safety standard operating procedures.

FDA Updates Guidance On Labeling Passive Implants For MRI

The agency has revised a 2008 guidance to spell out when it is OK to state in labeling that a non-electronic, or passive, implant has not been evaluated for safe use in a magnetic resonance environment, among other clarifications.

Research In Brief

Safe MRI with cardiac implants

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030684

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel